Pyruvate dehydrogenase kinase 1 (PDK1) (PDK1)

The Pyruvate Dehydrogenase Complex (PDC) / Pyruvate Dehydrogenase Kinase 1 (PDK1) axis serves as a fundamental gatekeeper of aerobic respiration by regulating the entry of glycolytic products into the mitochondrial tricarboxylic acid (TCA) cycle [1, 2]. PDK1 is a mitochondrial serine kinase that phosphorylates and inactivates the E1 alpha subunit of the PDC, thereby inhibiting the conversion of pyruvate into acetyl-CoA and shifting metabolism toward lactate production [1, 7]. In many pathological states, particularly cancer, PDK1 is upregulated by factors such as HIF-1 alpha, leading to the suppression of mitochondrial oxidation and the promotion of aerobic glycolysis, a phenomenon known as the Warburg effect [3, 4]. This metabolic reprogramming supports the biosynthetic demands of rapidly dividing cells and provides a survival advantage in hypoxic tumor environments [4, 5]. Pharmacological inhibition of PDK1 aims to reactivate the PDC, thereby restoring mitochondrial function, increasing reactive oxygen species (ROS) production, and inducing apoptosis in malignant cells [5, 6]. Beyond oncology, modulating this axis is explored for treating metabolic diseases like type 2 diabetes and cardiovascular conditions where enhancing glucose oxidation is therapeutically beneficial [2, 7].

Other names

PDHK1Pyruvate dehydrogenase [lipoamide] kinase isozyme 1, mitochondrialPDC/PDK1 axisPyruvate dehydrogenase kinase isoform 1

Inhibition of PDK1 prevents the phosphorylation and inactivation of the E1 alpha subunit of the Pyruvate Dehydrogenase Complex (PDC), thereby promoting the conversion of pyruvate to acetyl-CoA and increasing mitochondrial oxidative phosphorylation.